This webpage can include promotional content regarding one or several products of Sophysa, or some procedures concerning the use or implantation of such products.
This webpage is exclusively intended for healthcare professionals and is in no event directed to the general public.
Sophysa started operations in 1976 in France, and set a significant milestone in 1985 with the introduction of the world’s first programmable valve Sophy®. This represented a major advance in the treatment of hydrocephalus. The development of the Sophy® valve has contributed to the improvement of surgical management by allowing neurosurgeons to modify the operating pressure of the valve through the skin, and adapt it to the precise clinical needs of each patient. This reduces the number of surgical reoperations and allows patients a greater chance of full recovery without the need for invasive, secondary surgery.
In 1989, Sophysa joined TOKIBO group. The company quickly expanded in France, and gained global recognition for its innovative products and expertise in the field of neurosurgery. To consolidate its lead, Sophysa perfected the concept of the adjustable valve in 2004 with the Polaris®. This was the first MRI-Stable valve (magnetic resonance imaging (MRI) systems up to 3T and daily life magnetic fields), thanks to a security lock designed to avoid dysadjustments. The company innovated again in 2005 with Pressio®, an intracranial pressure monitoring system based on micro-sensors used in neurosurgical intensive care units and in neurotraumatology. In 2007, the next generation Pressio®2 Catheters was launched, offering a unique solution for the joint continuous measurements of intracranial pressure and temperature.
At Sophysa, each employee is committed to respecting the company’s values and beliefs, in all our actions and projects.
Innovation
The same passion drives all our employees at Sophysa: a unique combination of research, innovation and industrial excellence. Since our creation, we have brought to the market a series of innovative solutions that have become worldwide references.
In the landscape of neurosurgery and head trauma, Sophysa always remains at the heart of the brain, to assert its exclusive commitment to neurological disorders.
Ambition
Sophysa’s ambition to become the world reference in neurological valves and neuromonitoring systems is the result of an innovative creation process in a niche market, a close collaboration with the scientific community, as well as the development of dedicated partnerships with more than 70 distributors worldwide.
Excellence
As a true representative of French excellence, Sophysa maintains French know-how with a manufacturing system based on the art craftsmanship.
With its factory located in Besançon, the French capital of micro-mechanisms and mechanical watchmaking components, Sophysa is a model of finesse, precision and accuracy: every detail counts.
Our products are all hand-assembled and individually tested to meet the highest quality standards.
Integrity
With patients always at the heart of our design, we at Sophysa are committed to working tirelessly to provide the hospital market with products that meet the real needs of the market and the highest standards of quality and safety to ensure better management of cerebrospinal fluid related conditions.
In all our activities, we guarantee total integrity in our practices: whether they are commercial, HR related, financial or regulatory.
